Company Profile

Cadus Corporation (AKA: Cadus Pharmaceutical Corporation~Cadus Technologies)
Profile last edited on: 9/25/15      CAGE:       UEI:

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
1992
First Award
1997
Latest Award
1997
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

767 5th Avenue
New York, NY 10153
   (212) 702-4315
   N/A
   N/A
Location: Single
Congr. District: 12
County: New York

Public Profile

After a substantial investment by Ichan Enterprises, Cadus Corporation now focuses on real estate acquisition, renovation, and construction activities in Florida. Previously, Cadus Corporation, doing bsuiness as Cadus Pharmaceutical Corporation, the sought to license, through its subsidiary, Cadus Technologies, Inc., drug discovery technologies. The Company had devoted substantially all of its resources to the development and application of novel yeast-based and other drug discovery technologies until July 30, 1999. In December 2001, Cadus formed a wholly owned subsidiary, Cadus Technologies, Inc., and transferred all of its patents, patent applications, know-how, licenses and drug-discovery technologies to the subsidiary. Given limited business impact, decision was made entirely to refocus business endeavors.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
150-249
Revenue Range
15M-20M
VC funded?
Yes
Public/Private
Publicly Traded
Stock Info
OTC : KDUS
IP Holdings
25-49

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
1997 1 NIH $100,000
Project Title: Screen--Regulator Of Hematopoietic Cell Restricted Ptp1c
1997 1 NIH $92,323
Project Title: Drug Screen(S) Targeting Sh3 Interactions In Allergy

Key People / Management

  David Blitz -- President

  Hunter Gary -- President and CEO

  Russell Glass

  Christopher M Pleiman

Company News

There are no news available.